Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

GW Pharmaceuticals

4 Disclosed Funding Rounds $568,100,000

0 Participating Investments


Pharmaceutical, Therapeutics, Health Care, Biotechnology, Cannabis

GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.

Histon, Cambridgeshire, United Kingdom, Europe (GB)

Organizations in Histon in Pharmaceutical,
Organizations in Histon in Therapeutics,
Organizations in Histon in Health Care,
Organizations in Histon in Biotechnology,
Organizations in Histon in Cannabis,
Organizations in Cambridgeshire in Pharmaceutical,
Organizations in Cambridgeshire in Therapeutics,
Organizations in Cambridgeshire in Health Care,
Organizations in Cambridgeshire in Biotechnology,
Organizations in Cambridgeshire in Cannabis,
Organizations in United Kingdom in Pharmaceutical,
Organizations in United Kingdom in Therapeutics,
Organizations in United Kingdom in Health Care,
Organizations in United Kingdom in Biotechnology,
Organizations in United Kingdom in Cannabis,
Organizations in Europe in Pharmaceutical,
Organizations in Europe in Therapeutics,
Organizations in Europe in Health Care,
Organizations in Europe in Biotechnology,
Organizations in Europe in Cannabis

Investors in Histon in Pharmaceutical,
Investors in Histon in Therapeutics,
Investors in Histon in Health Care,
Investors in Histon in Biotechnology,
Investors in Histon in Cannabis,
Investors in Cambridgeshire in Pharmaceutical,
Investors in Cambridgeshire in Therapeutics,
Investors in Cambridgeshire in Health Care,
Investors in Cambridgeshire in Biotechnology,
Investors in Cambridgeshire in Cannabis,
Investors in United Kingdom in Pharmaceutical,
Investors in United Kingdom in Therapeutics,
Investors in United Kingdom in Health Care,
Investors in United Kingdom in Biotechnology,
Investors in United Kingdom in Cannabis,
Investors in Europe in Pharmaceutical,
Investors in Europe in Therapeutics,
Investors in Europe in Health Care,
Investors in Europe in Biotechnology,
Investors in Europe in Cannabis

Founded date 01, 1998

Founders Geoffrey Guy, Brian Whittle

Operating Status Active

Funding Stage M&A

Last Funding Type Post-IPO Equity

Company Type For Profit


LinkedIN Link

Wikipedia Link

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Date Round Raised Lead
October, 02, 2018 Post-IPO Equity $300,000,000 -------
March, 03, 2017 Post-IPO Equity $1,000,000 -------
April, 29, 2015 Post-IPO Equity $179,200,000 -------
January, 08, 2014 Post-IPO Equity $87,900,000 -------

GW Pharmaceuticals Investors (1)

Investor Lead? Round Participating Raise Date Partners
Mentor Capital No Post-IPO Equity $1,000,000 March, 03, 2017 -------